

IPW
S/N 10/000,452

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McGrogan
Examiner: Robert C. Hayes
Serial No.: 10/000,452
Group Art Unit: 1649
Filed: December 4, 2001
Docket: LAY-007ORD
Title: Production and Use of Dopaminergic cells to treat dopaminergic deficiencies

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b)(3), Applicants are filing this IDS before the mailing of the first Office action on the merits in this application. Therefore, it is believed that no fee is due. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication or if a fee is due.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicants believe that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicants have not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicants respectfully request that notice of such requirement be directed to Applicants' below-

INFORMATION DISCLOSURE STATEMENT

Serial No :10/000,452

Filing Date: December 4, 2001

Title: Production and Use of Dopaminergic cells to treat dopaminergic deficiencies

Page 2

Dkt: LAY-007ORD

signed representative. Applicants acknowledge the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

By their Representative,

Date March 14, 2006
The Luther Law Firm, PLC
12198 E. Columbine Dr.
Scottsdale, AZ 85259
Tel: 480-275-8302
Fax: 480-275-8303

By Barbara J. Luther
Barbara J. Luther
Reg. No. 33,954

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 14 day of March, 2006.

Name Barbara J. Luther

Barbara J. Luther
Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

| | |
|-----------------------------|------------------|
| Application Number | 10/000,452 |
| Filing Date | December 4, 2001 |
| First Named Inventor | McGrogan |
| Art Unit | 1649 |
| Examiner Name | Robert C. Hayes |

Attorney Docket No: LAY-007ORD

US PATENT DOCUMENTS

| Examiner Initial * | Cite No | USP Document Number | Publication Date | Name of Patentee or Applicant of cited Document | Filing Date If Appropriate |
|--------------------|---------|---------------------|------------------|---|----------------------------|
| | | US-5175103 | 12/29/1992 | Lee, Virginia et al. | 10/21/1991 |
| | | US-5411883 | 05/02/1995 | Boss, Barbara D., et al. | 08/12/1992 |
| | | US-5654183 | 08/05/1997 | Anderson et al. | 01/28/1994 |
| | | US-5750376 | 05/12/1998 | Weiss, Samuel et al. | 06/07/1995 |
| | | US-5753506 | 05/19/1998 | Johe | 09/25/1996 |
| | | US-5843780 | 12/01/1998 | Thomson | 01/18/1996 |
| | | US-5981165 | 11/09/1999 | Weiss, Samuel | 06/07/1995 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Foreign Document No | Publication Date | Name of Patentee or Applicant of cited Document | T ² |
|--------------------|---------------------|------------------|---|----------------|
| | WO-00/06700 | 02/10/2000 | McGrogan, Michael , et al. | |
| | WO-90/06757 | 06/28/1990 | Gage, Fred H., et al. | |
| | WO-96/15224 | 05/23/1996 | Weiss, Samuel , et al. | |
| | WO-97/33470 | 09/18/1997 | Sanberg, Paul R. | |
| | WO-99/56759 | 11/11/1999 | McGrogan, Michael | |
| | WO-94/10292 | 05/11/1994 | Weiss, Samuel , et al. | |
| | WO-96/15224 | 05/23/1996 | Weiss, Samuel | |
| | WO-97/33470 | 09/18/1997 | Sanberg, Paul R. , et al. | |

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|----------------------|---|----------------|
| | | ADAMS, F.S. , et al., "Characterization and transplantation of two neuronal cell lines with dopaminergic properties", <u>Chem. Res.</u> 21(5), (1996),619-27 | |
| | | ANDREWS, P. , et al., "Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2", <u>Lab. Invest.</u> 50(2), (1984),147-62 | |
| | | BAKER, K.A. , "Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's Disease", <u>Exp. Neurol.</u> 162(2), (2000),350-60 | |
| | | BECKER, R. , et al., "Lithium enhances the proliferation of HL-60 promyelocytic leukemia cells", <u>Leukemia Res.</u> 14(10), (1990),879-84 | |
| | | CENTENO, F. , et al., "Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons", <u>Neuroreport</u> 9(18), (1998),4199-4203 | |

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***Complete if Known*

| | |
|-----------------------------|------------------|
| Application Number | 10/000,452 |
| Filing Date | December 4, 2001 |
| First Named Inventor | McGrogan |
| Art Unit | 1649 |
| Examiner Name | Robert C. Hayes |

(Use as many sheets as necessary)

Sheet

2

of

5

Attorney Docket No: LAY-007ORD

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|----------------------|---|----------------|
| | | CHEN, G. , et al., "Increase in AP-1 transcription factor DNA binding activity by valproic acid", <u>Neuropsychopharmacology</u> 16(2), (1997),238-45 | |
| | | D'MELLO, S.R. , et al., "Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons", <u>Exp. Cell Res.</u> 211(2), (1994),332-38 | |
| | | FRIEDMAN, et al., "Effect of lithium on brain dopamine", <u>Nature</u> 243, (1973),520-21 | |
| | | GARCIA-PEREZ, JULIA , et al., "Lithium induces morphological differentiation of mouse neuroblastoma cells", <u>J. Neurosci. Res.</u> 57, (1999),261-70 | |
| | | GRIGNON, S. , et al., "Tyrosine kinase inhibitors and cycloheximide inhibit lithium protection of cerebellar granule neurons switched to non-depolarizing medium", <u>Eur. J. Pharmacol</u> 315(1), (1996),111-14 | |
| | | HARTLEY, R. , et al., "Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT)", <u>J. Comparative Neurol.</u> 415(3), (1999),404-17 | |
| | | HASGEKAR, N.N. , et al., "Lithium inhibits growth in a murine neural precursor cell line", <u>Cell Biol.</u> 20(12), (1996),781-86 | |
| | | HOLLANDER, B. A. , et al., "Lithium chloride alters cytoskeletal organization in growing, but not mature, cultured chick sensory neurons", <u>J. Neurosci. Res.</u> 28(3), (1991),332-42 | |
| | | HONG, M. , et al., "Lithium reduces tau phosphorylation by inhibition of glycogen synthetase kinase-3", <u>J. Biol. Chem.</u> 272(40), (1997),25326-32 | |
| | | IACOVITI, LORRAINE , "Expression of tyrosine hydroxylase in newly differentiated neurons from a human cell line (hNT)", <u>Neuroreport</u> 8, (1997),1471-4 | |
| | | JOHNSON, G. , "Lithium in depression: a review of the antidepressant and prophylactic effects of lithium", <u>Australian and New Zealand J. Psychiatry</u> 21(3), (1987),356-65 | |
| | | KAPLAN, H.I. , "Ch. 9, Mood Disorders", <u>Concise Textbook of Clinical Psychiatry</u> , Williams & Wilkins, (1996),159-188 | |
| | | LAMOUREUX, P. , et al., "Extracellular matrix allows PC12 neurite elongation in the absence of microtubules", <u>J. Cell Biol.</u> 110(1), (1990),71-79 | |
| | | LANGEVALD, CORNELIUS H., et al., "Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development", <u>Neurosci. Lett.</u> 192, (1995),13-16 | |

EXAMINER**DATE CONSIDERED**

| | | | |
|--|---|----|---|
| Substitute for form 1449A/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Sheet | 3 | of | 5 |
| Attorney Docket No: LAY-007ORD | | | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------------------|---|----------------|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | LEE, V., et al., "hNT neurons: human postmitotic CNS neurons", <u>Strat. Mol. Biol.</u> 7, (none), 28-31 | |
| | | LI, "Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells", <u>J. Neurosci.</u> 65, (1995), 2500-08 | |
| | | LINDVALL, "Engineering neurons for Parkinson's disease", <u>Nature Biotechnology</u> 17, (1999), 635-6 | |
| | | LING, "Differentiation of mesencephalic progenitor cells...", <u>Exp. Neurol.</u> 149, (1998), 411-23 | |
| | | LOPEZ-LOZANO, J., "Long-term improvement in patients with severe Parkinson's Disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-yr follow up in 10 patients.", <u>J. Neurosurg.</u> 86, (1997), 931-42 | |
| | | LUCAS, FIONA R., et al., "Inhibition of GSK-3 beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium", <u>J. Cell Sci.</u> 111, (1998), 1351-61 | |
| | | LUCAS, F., et al., "WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons", <u>Dev. Biol.</u> 192(1), (1997), 31-44 | |
| | | MENA, MARIA A., "Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: prevention of cell death by dibutyryl cyclic AMP", <u>J. Neurochem.</u> 65(6), (1995), 2612-20 | |
| | | MENDEZ, "Reconstruction of the nigrostriatal pathway by simultaneous intrastratal and intranigral dopaminergic transplants", <u>J. Neurosci.</u> 16, (1996), 7216-27 | |
| | | MIYAZONO, M., et al., "Long-term integration and neuronal differentiation of human embryonal carcinoma cells (NTera-2) transplanted into the caudatoputamen of nude mice", <u>J. Compar. Neurol.</u> 376(4), (1996), 603-13 | |
| | | MURRAY, R.K., "Ch. 64. Biochemical basis of some neuropsychiatric disorders", <u>Harper's Biochemistry</u> 24 ed., Appleton & Lange, (1996), 793-813 | |
| | | NONAKA, S., et al., "Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx", <u>J. Neurochem.</u> 69(5), (1998), 2642-47 | |
| | | NONAKA, S., et al., "Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine", <u>J. Pharmacol. Exp. Therap.</u> 286(1), (1998), 539-47 | |

EXAMINER

DATE CONSIDERED

| | | | |
|--|---|----|---|
| Substitute for form 1449A/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Sheet | 4 | of | 5 |
| Attorney Docket No: LAY-007ORD | | | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------------------|---|----------------|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | NONAKA, S. , et al., "Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats", <u>Neuroreport</u> 9(9), (1998),2081-84 | |
| | | ORKIN, S. H., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy", <u>December</u> , (1995),1-41 | |
| | | OZAKI, N. , et al., "Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain", <u>J. Neurochem</u> 69(6), (1997),2336-44 | |
| | | PEKOSZ, "Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention", <u>J. Virology</u> 70, (1996),5329-5335 | |
| | | PLEASURE, SAMUEL , "Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons", <u>J Neurosci</u> 12, (1992),1802-15 | |
| | | ROSENBLAD, "Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts", <u>Neuroscience</u> 75, (1996),979-85 | |
| | | SANBERG, PAUL R., "Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats", <u>Nature Medicine</u> 3, (1997),1129-32 | |
| | | SAPORTA, S. , et al., "In vitro and in vivo characterization of hNT neuron neurotransmitter phenotypes", <u>Brain Res. Bull.</u> 53(3), (2000),263-68 | |
| | | SEGAL, D. , et al., "Alterations in behavior and catecholamine biosynthesis induced by lithium", <u>Nature</u> 254 (5495), (1975),58-59 | |
| | | SENTMAN, "bcl-2 inhibits multiple forms of apoptosis... (abstract)", <u>Cell</u> 67(5), (1991),879-88 | |
| | | TERAO, TAKESHI , "Lithium Chloride Stimulates Catecholamine Synthesis and secretion in Cultured bovine adrenal medullary cells", <u>Biol Psychiatry</u> 31, (1992),1038-49 | |
| | | UNLAP, M.T. , et al., "Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells", <u>Neuropsychopharmacology</u> 17(1), (1997),12-17 | |
| | | VERMA, I. M., "Gene therapy - promises, problems and prospects", <u>Nature</u> 389, (1997),239-42 | |
| | | WAGNER, "Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by Type 1 astrocytes", <u>Nature Biotechnology</u> 17, (1999),635-59 | |

EXAMINER

DATE CONSIDERED

| | | | |
|--|------------------|----|---|
| Substitute for form 1449A/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Application Number | 10/000,452 | | |
| Filing Date | December 4, 2001 | | |
| First Named Inventor | McGrogan | | |
| Art Unit | 1649 | | |
| Examiner Name | Robert C. Hayes | | |
| Sheet | 5 | of | 5 |
| Attorney Docket No: LAY-007ORD | | | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------------------|---|----------------|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | YUAN, P.X. , et al., "The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth", <u>J. Biol. Chem.</u> 276(34), (2001),31674-83 | |
| | | ZHANG, X., et al., "Inhibitory actions of ropivacaine on tumor necrosis factor-alpha-induced leukocyte adhesion and tissue accumulation in vivo", <u>Eur. J. Pharmacol.</u> 392(1/2), (2000),R1-R3 | |
| | | ZIGOVA, T. , et al., "Apoptosis in cultured hNT neurons", <u>Dev. Brain Res.</u> 127, (2001),63-70 | |
| | | ZIGOVA, T. , et al., "Dopaminergic phenotype of hNT cells in vitro", <u>Dev. Brain Res.</u> 122, (2000),87-90 | |
| | | ZIGOVA, T. , et al., "Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons", <u>Exp. Neurol.</u> 157(2), (1999),251-58 | |
| | | ZIGOVA, T. , et al., "Neural stem cells for brain repair", <u>Science & Medicine</u> September/October, (1999),18-27 | |

EXAMINER

DATE CONSIDERED